Saniona AB
STO:SANION

Watchlist Manager
Saniona AB Logo
Saniona AB
STO:SANION
Watchlist
Price: 8.12 SEK 0.62% Market Closed
Market Cap: 903.3m SEK
Have any thoughts about
Saniona AB?
Write Note

Saniona AB
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Saniona AB
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Saniona AB
STO:SANION
Gross Profit
-kr22.9m
CAGR 3-Years
53%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Gross Profit
kr18.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Gross Profit
kr55.4m
CAGR 3-Years
-23%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Gross Profit
€277.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Gross Profit
kr3.5B
CAGR 3-Years
91%
CAGR 5-Years
62%
CAGR 10-Years
19%
Bioporto A/S
CSE:BIOPOR
Gross Profit
kr24.1m
CAGR 3-Years
19%
CAGR 5-Years
6%
CAGR 10-Years
8%
No Stocks Found

Saniona AB
Glance View

Market Cap
903.3m SEK
Industry
Biotechnology

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

SANION Intrinsic Value
3.56 SEK
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Saniona AB's Gross Profit?
Gross Profit
-22.9m SEK

Based on the financial report for Jun 30, 2024, Saniona AB's Gross Profit amounts to -22.9m SEK.

What is Saniona AB's Gross Profit growth rate?
Gross Profit CAGR 5Y
9%

Over the last year, the Gross Profit growth was 22%. The average annual Gross Profit growth rates for Saniona AB have been 53% over the past three years , 9% over the past five years .

Back to Top